Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain by Pergolizzi Jr., Joseph V. et al.
© 2012 Pergolizzi Jr et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Journal of Pain Research 2012:5 327–346
Journal of Pain Research
Tramadol/paracetamol fixed-dose combination  
in the treatment of moderate to severe pain
Joseph V Pergolizzi Jr1,2
Mart van de Laar3
Richard Langford4
Hans-Ulrich Mellinghoff5
Ignacio Morón Merchante6
Srinivas Nalamachu7,8
Joanne O’Brien9
Serge Perrot10
Robert B Raffa11
1Department of Medicine, Johns 
Hopkins University, Baltimore, 
MD, USA; 2Association of Chronic 
Pain Patients, Houston, TX, USA; 
3Arthritis Center Twente (MST and 
UT), Enschede, The Netherlands; 
4Anaesthetics Laboratory,  
St Bartholomew’s Hospital, London, 
UK; 5Department of Endocrinology, 
Diabetology and Osteology, 
Kantonsspital St Gallen, St Gallen, 
Switzerland; 6Centro de Salud 
Universitario Goya, Madrid, Spain; 
7Kansas University Medical Center, 
Kansas City, KS, USA; 8International 
Clinic Research, Leawood, KS, USA; 
9Department of Pain Management, 
Beaumont Hospital, Beaumont, Dublin, 
Ireland; 10Service de Médecine Interne 
et Consultation de la Douleur, Hôpital 
Dieu, Paris, France; 11Department 
of Pharmaceutical Sciences, Temple 
University School of Pharmacy, 
Philadelphia, PA, USA
Correspondence: Joseph V Pergolizzi Jr 
NEMA Research, Inc, 840-111th 
Avenue N, Naples, FL 34108-1877, USA 
Tel +1 239 597 3662 
Fax +1 239 597 7566 
Email jpjmd@msn.com
Abstract: Pain is the most common reason patients seek medical attention and pain relief has 
been put forward as an ethical obligation of clinicians and a fundamental human right. However, 
pain management is challenging because the pathophysiology of pain is complex and not 
completely understood. Widely used analgesics such as nonsteroidal anti-inflammatory drugs 
(NSAIDs) and paracetamol (acetaminophen) have been associated with adverse events. Adverse 
event rates are of concern, especially in long-term treatment or at high doses. Paracetamol and 
NSAIDs are available by prescription, over the counter, and in combination preparations. Patients 
may be unaware of the risk associated with high dosages or long-term use of paracetamol and 
NSAIDs. Clinicians should encourage patients to disclose all medications they take in a “do 
ask, do tell” approach that includes patient education about the risks and benefits of common 
pain relievers. The ideal pain reliever would have few risks and enhanced analgesic efficacy. 
Fixed-dose combination analgesics with two or more agents may offer additive or synergistic 
benefits to treat the multiple mechanisms of pain. Therefore, pain may be effectively treated 
while toxicity is reduced due to lower doses. One recent fixed-dose combination analgesic 
product combines tramadol, a centrally acting weak opioid analgesic, with low-dose paracetamol. 
Evidence-based guidelines recognize the potential value of combination analgesics in specific 
situations. The current guideline-based paradigm for pain treatment recommends NSAIDs for 
ongoing use with analgesics such as opioids to manage flares. However, the treatment model 
should evolve how to use low-dose combination products to manage pain with occasional use 
of NSAIDs for flares to avoid long-term and high-dose treatment with these analgesics. A next 
step in pain management guidelines should be targeted therapy when possible, or low-dose 
combination therapy or both, to achieve maximal efficacy with minimal toxicity.
Keywords: NSAIDs, opioids, combination analgesics, moderate pain, severe pain, analgesics, 
tramadol/paracetamol
Introduction
Pain is the oldest medical problem and has been a challenge for doctors since the 
origin of humanity. While scientific and technological breakthroughs have improved 
care in many areas, eradicating diseases and advancing longevity, pain remains a 
global public health issue. The World Health Organization (WHO) has promoted and 
disseminated guidelines on pain management,1 advocated for the use of analgesics, 
including opioids,2 and encouraged national programs for palliative care and the relief 
of cancer pain.3,4 Pain relief has been put forward as a fundamental human right.5–8 
The third international symposium on the Societal Impact of Pain held in May 2012 
in Copenhagen has finalized a position paper, seeking that chronic pain be recognised 
as a disease by the governments of member states.9 Despite pharmacological advances 
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and numerous guidelines or  consensus documents to inform 
clinicians about the appropriate prescribing of analgesics, 
pain is often under-treated.10–12 Inadequate analgesia may 
have roots in social, political, legal, cultural, and religious 
considerations, as well as the fundamental knowledge, 
 differences in health care systems, and variations in clinical 
practice.13–16 However, it remains the imperative of medical 
professionals to relieve pain as much as possible.17–19 
Regardless of the social and political factors complicating 
analgesic therapy, not treating pain is not an option and has 
been described as a “moral outrage.”20
The European Study of the Epidemiology of Mental 
Disorders reported from a questionnaire (1659 respondents, 
all of whom were $75 years of age) that pain was the most 
commonly reported problem in this population (55.2%), far 
exceeding the rate of depression and anxiety (11.6%).21 In 
Europe, it is estimated that 19% of the general population suf-
fers from chronic pain.22 A hospital-based survey in Germany 
reported that over 80% of patients (n = 438) experienced pain 
in the previous 3 months and pain was the main reason for 
hospital admission in over 60% of the cases.23 In the USA, 
chronic pain affects more people every year than diabetes, 
heart disease, and cancer combined.24,25 Chronic pain can 
occur in patients of any age, but it is more common among 
older individuals.26 Inadequately treated persistent pain may 
be associated with a number of adverse outcomes in older 
people, including functional impairment, reduced mobility, 
falls, slower rehabilitation, decreased socialization, inad-
equate sleep, disturbed appetite, and changes in mood.27 Pain 
negatively affects quality of life, adversely affects families, 
may result in lost or diminished productivity for society, and 
places a large burden on the health care system. In the USA 
in 2002–2003, over US$4 billion was spent on headache-
related care alone, and this did not include over-the-counter 
medications, self-treatment, and inpatient treatment.28 The 
total global health care burden related to all types of acute 
and chronic pain syndromes is difficult to assess.
Although pain management guidelines address specific 
types of pain, they frequently recommend nonsteroidal 
anti-inflammatory drugs (NSAIDs) in cases where tissue 
damage and inflammation are absent. Due to serious gastro-
intestinal, cardiovascular, and renal side effects, caution is 
recommended when using high-dose NSAIDs, particularly 
when taken long-term.27,29 The appropriate use of NSAIDs, 
paracetamol, opioid analgesics, or combination products in 
the chronic pain population remains a subject of ongoing 
research.
Meeting details
A consensus meeting attended by all authors of this  publication 
was held on November 20, 2010 in Paris, France, to discuss 
the use of high-dose NSAIDs, high-dose  paracetamol, or 
tramadol/paracetamol (as an example of fixed-dose com-
bination analgesics) for the management of moderate to 
severe pain from different etiologies. Tramadol/Paracetamol 
is – to our knowledge – the only fixed-dosed combination 
product where the dual mode of action of tramadol and the 
analgesic synergy between the two compounds have been 
proven in both preclinical studies (mouse model)30,31 and 
companion human studies.32,33 Presentations by five of the 
authors were followed by a group discussion and review of 
pain management issues regarding these drug classes and 
available guidelines/recommendations based on the clinical 
experiences of the participants. A manuscript was drafted, 
additional articles were reviewed and incorporated, and a 
final consensus was adopted by the group.
Pain management and underlying 
pain mechanisms
Pain management is complex for many reasons. Chronic pain 
may be broadly classified into nociceptive (pain owing to 
 tissue disease or damage, including inflammatory and visceral 
pain), neuropathic (pain caused by somatosensory system 
disease or damage), and mixed syndromes  (coexistence 
of nociceptive and neuropathic pain).34 However, even the 
terminology of pain becomes challenging and contentious.35 
For example, the International Association for the Study 
of Pain is currently attempting to distinguish between 
“nociception” (a sensory process) and “pain” (a subjective 
phenomenon).36
Multiple mechanisms contribute to painful syndromes, 
including nociception, peripheral sensitization, central 
sensitization, phenotypic switches, ectopic excitability, 
structural reorganization, and compromised inhibitory 
systems.37–41 Hypersensitivity causes a mild stimulus to pro-
voke pain out of proportion to the stimulus. Hypersensitivity 
may be categorized academically as allodynia (pain response 
to nonnociceptive stimuli) or hyperalgesia (increased pain 
sensitivity in response to nociceptive stimuli),37 although 
these phenomena may be difficult to distinguish clinically.
The mechanisms may act in different ways. Nociception 
requires an intact central nervous system; changes in the 
central nervous system are evident in chronic pain patients.42 
Primary afferent or sensory neurons play an important role 
in nociceptive pain processing, thus involving the peripheral 
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nervous system.42 Inflammation, altered sympathetic and 
catecholaminergic function, changes in somatosensory 
processing in spinal cord and brain, pressure, temperature, 
neuropathic components, along with psychological factors, 
may also play a role in acute and chronic pain syndromes.43 
The transition from acute to chronic pain is not thoroughly 
understood, but it is likely to involve the interaction among 
immune, endocrine, and nervous systems44 and, therefore, 
progressing central and peripheral sensitization.45 Other 
factors no doubt play a role. A study of trauma patients 
(n = 290) identified as risk predictors for the transition to 
chronic pain – that is, pain that persists beyond 3 months: 
older age, female sex, past alcohol dependence, the amount of 
morphine equivalents administered on the day of assessment, 
and attitudes about pain control.46 A two-dimension positron 
emission tomography scan study of 20 cancer patients 
found preferential activation of the prefrontal cortex in 
patients with chronic pain but not in similar patients without 
pain.47 The prefrontal cortex is associated with emotional 
response, which may account for the emotional component 
of chronic pain.
In certain rheumatic pain conditions, selective serotonin 
reuptake inhibitors, serotonin and noradrenalin reuptake 
inhibitors, as well as tricyclic antidepressants have been 
shown to exert an analgesic effect that is distinct from their 
ability to treat depression, fatigue, and sleep disturbances.48,49 
However, the evidence for the efficacy of these drugs in 
treating common pain syndromes (headache, low back pain, 
fibromyalgia, postherpetic neuralgia, and others) remains 
equivocal and, at times, conflicting.50,51 This suggests that 
these common pain syndromes may involve different pain 
mechanisms.
The accurate assessment of pain is challenging because 
pain perception is subjectively reported and may be influ-
enced by the patient’s attitude about health, disease, and 
personal expectations.52 These differences may be more than 
just idiosyncratic. For example, men and women not only 
experience pain differently, they may respond to analgesics 
differently.53
Pain may be a potentially serious comorbid condition, 
affecting medical and surgical outcomes.23 Maladaptive 
chronic pain may even be regarded as a disease in its own 
right.37 As such, it is crucial to devote our attention to better 
understanding and superior management of patients dealing 
with acute and chronic pain. The identification and increased 
understanding of the multiple mechanisms of pain has been 
a major advance.
Commonly used agents  
in the treatment of pain
Since the dawn of medicine, clinicians have treated pain 
(Table 1). As early as 3000 BC, natural salicylates were applied 
for the treatment of pain and Hippocrates reported on the 
analgesic efficacy of opium as early as 400 BC. However, in 
early medicine, these narcotics enjoyed a dubious reputation 
because of their potential for misuse, potentially life-threatening 
side effects, and withdrawal symptoms.54 Chemistry-based 
anti-inflammatory therapy began in 1897 with the discovery of 
aspirin, leading to advances in other pharmacological options, 
including NSAIDs. In 1986, the WHO proposed its well-known 
“pain ladder,” which calls for the treatment of cancer pain based 
on level of pain intensity rather than the underlying mechanism, 
in that it advocates the use of nonopioid agents (such as aspirin, 
paracetamol, and NSAIDs) for mild pain, weak opioids for 
moderate pain (tramadol), and strong opioids (morphine) for 
severe pain.1 The multimechanistic nature of pain is recognized 
in the WHO ladder insofar as it includes adjuvant medications 
to treat pain.
When the WHO ladder was introduced in 1986, 
oxycodone, hydromorphone, and buprenorphine did not 
exist. Tramadol was not available worldwide until the 1990s. 
Transdermal delivery systems for opioids were unknown 
in 1986. Methadone, not listed on the WHO pain ladder, 
existed in 1986, but its analgesic benefits in treating cancer 
pain were unknown. The first guidelines for neuropathic 
pain management were not published until the first decade 
of the 21st century55–58 and the neuropathic treatment model 
differs from the WHO ladder (opioids are adjuvants in 
neuropathic pain management). Thus, in particular, the pain 
model should be updated with new pharmacological agents 
(new opioids, gabapentinoids, etc) according to new insights 
into adjuvant and multimodal therapies.59 It should also 
be noted that all treatment options may be combined with 
nonpharmacological approaches and patients may benefit 
from these multidisciplinary efforts.
Weighing the risks of treatment 
with high-dose NSAIDs  
and paracetamol
Paracetamol or acetaminophen is frequently grouped 
with NSAIDs, but it is actually an aniline analgesic. The 
terms “paracetamol” and “acetaminophen” reflect only 
geographical differences: “acetaminophen” is the term used 
in the USA, Canada, Hong Kong, Iran, and certain Latin 
American countries, such as Colombia, while “paracetamol” 
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is used in Europe, Africa, and most of Asia. The drug 
is sometimes abbreviated to “APAP” in all geographic 
regions. The mechanism of action of paracetamol is not well 
understood and several models have been proposed, all of 
which have certain strengths and limitations.60 Paracetamol 
is metabolized mainly by conjugation with sulfate and 
glucuronide, with about 5% to 10% of the drug oxidized by 
the cytochrome P450 metabolic pathway (mostly CYP2E1 
and CYP3A4) to a toxic electrophilic metabolite, N-acetyl-
p-benzoquinone imine (NAPQI). NAPQI is subsequently 
detoxified by glutathione and eliminated in the urine or 
bile.61 If any residual NAPQI is not detoxified in this 
manner, it may bind to hepatocytes, where it can lead to 
cellular necrosis. At appropriate doses in healthy individuals, 
the small amounts of NAPQI produced by paracetamol 
metabolism can be effectively eliminated with glutathione. 
However, at higher doses, paracetamol is associated with 
serious hepatic toxicity.62 In fact, paracetamol toxicity is 
the leading indication for liver transplantation in the UK63 
and one of the most common causes of poisoning64 and 
acute liver failure65 in the USA. Paracetamol has also been 
linked to hypertension,66–68 which is probably caused by the 
considerable sodium content present in each paracetamol 
tablet. Thus, there are still unanswered questions about these 
side effects, including their extent.69–71
NSAIDs encompass a diverse group of drugs that reduce 
pronociceptive and proinflammatory prostaglandins and other 
chemical mediators by inhibiting their biotransformation in the 
arachidonic cascade, a reaction catalyzed by cyclooxygenase 
(COX) isoenzymes.72 In this way, they are similar to aspirin.73
The safety of many drugs, including pain drugs, has 
not been studied in as much detail as safety issues of 
NSAIDs and especially selective COX-2 inhibitors (coxibs). 
Nonselective NSAIDs block COX, namely COX-1 and 
Table 1 Milestones in analgesic agents
Year Event
3000 BC First description of the use of myrtle leaves as systemic pain treatment
Approximately 400 BC Hippocrates reports on the pain-relieving properties of opium in treating internal diseases and diseases of women
1527 Paracelsus prescribes opium with other agents as an analgesic
1680 Thomas Sydenham introduces Sydenham’s laudanum (opium mixed with wine and herbs), which becomes a 
popular home remedy
1803 Friedrich Sertürner discovers the active ingredient in opium – morphine
1827 Merck and Company begin first commercial manufacture of morphine
1877 Synthesis of paracetamol (acetaminophen) at Johns Hopkins University is completed, but the drug would not be 
used in patients for another 10 years
1890 Morphine, legal in the USA, is taxed by Congress
1895 Bayer Company adds acetyls to morphine to reduce side effects to create a drug that would be marketed in 1898 
as Heroin (trade name)
1897 Discovery of aspirin, named for Spiraea (meadowsweet), one of many salicylate sources used to treat pain in the 
nineteenth century
1905 USA bans opium (but not opioid drugs)
1910 Heroin, marketed as a cough suppressant and morphine substitute, is taken off the market when it is found it is 
more addictive than morphine
1914 The Harrison Narcotics Act in the USA requires physicians and pharmacists who prescribe or dispense narcotics 
to register (and pay a tax)
1953 Paracetamol (acetaminophen) first marketed in the USA by Sterling-Winthrop Company
1955 McNeil Laboratories first markets Tylenol® brand (paracetamol) in the USA
1956 Frederick Stearns and Company first markets Panadol in the UK
1963 Development of nonsteroidal anti-inflammatory drugs (NSAIDs)
1971 Understanding of the mechanism of action of aspirin
1990–1991 Discovery of cyclooxygenase-2 (COX-2)
1992 COX-2 drug development
1998–1999 Celecoxib and rofecoxib introduced
2004–2006 Rofecoxib withdrawn from market
2005 Warning of increased cardiovascular risk must be added to labeling for all NSAIDs in US (FDA requirement)
2006–2010 Warnings and dose restrictions on NSAIDs
2009 Dextropropoxyphene withdrawn from market in the European Union
2010 FDA launches Safe Use Initiative
2010 Propoxyphene withdrawn from market in the USA
Abbreviation: FDA, US Food and Drug Administration.
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COX-2, blocking the synthesis of prostaglandins and 
consequently shunting arachidonic acid into the lipoxygenase 
pathway, producing leukotrienes. Leukotrienes are powerful 
bronchoconstrictors and impair mucociliary clearance, 
resulting in increased mucus production, mucus filtration, 
and edema. Obviously, NSAID use has been associated 
with bronchospasm.74 Coxibs selectively block COX-2 and 
include such drugs as celecoxib, valdecoxib, and rofecoxib, 
limiting the COX-1-related inhibition to vital housekeeping 
functions. All NSAIDs are associated with dose-dependent 
toxicity, manifesting as gastrointestinal symptoms, including 
dyspepsia, ulceration, and bleeding, as well as cardio-renal 
complications including fluid retention, hypertension, and 
renal dysfunction.75–77 A recent study found even short-term 
use of NSAIDs was associated with increased risk of death 
in patients with a history of myocardial infarction (hazard 
ratio 1.45; 95% confidence interval: 1.29–1.62).78
For such reasons, NSAIDs, including coxibs, should not 
be prescribed as a panacea for all pains, but restricted to pain 
related to tissue damage and/or inflammation, in accordance 
to their mechanism of action.79–81 NSAIDs are to be used 
cautiously, in patients with or at elevated risk for cardiovascular 
disease29,78,79,81–84 or gastrointestinal complications.79,81,85
Pharmacological aspects:  
why combinations might be  
better than single agents
Rarely does a single known mechanism cause pain. 
Obviously, no single analgesic agent can fully address 
 multiple mechanisms of pain. Combination analgesic 
 products have been effective because they activate multiple 
pain-inhibitory pathways and offer a broader spectrum of 
relief.86 This may include multiple afferents and pathways 
as well as multiple processes.
Combination analgesics might reduce adverse events.86 
A given analgesic provides pain relief at a specific dosage 
and is associated with dose-dependent adverse effects. 
Combining analgesics may allow for lower doses of the 
individual agents, with doses possibly low enough to 
significantly reduce potential adverse events. While the 
theory of combination analgesic products holds promise, 
combination products require rigorous scrutiny and testing 
since not all combinations are ideal.
Combining two or more agents may result in an additive or 
synergistic analgesic effect.86,87 When agents are combined, the 
combination effect may be greater than, less than, or the same 
as the predicted magnitude of effect, resulting in  synergistic, 
sub-additive, or additive effects, respectively. Such effects 
are calculated mathematically based on the concept of dose 
equivalence, defined as doses of each drug that yield the 
same magnitude of effect when each is used by itself. These 
calculations compare actual versus expected effects in graphic 
representations of dose combinations known as isoboles88–92 
(Figure 1). Isobolographic analysis is well accepted and has 
been used with many drug combinations.93,94 Drugs with a con-
stant potency ratio have linear isoboles of additivity,93–95 but 
drugs with variable potency ratios can be analyzed as well.96 
Receptor saturation of the agents can also be assessed.97
Combination analgesic products are common and include, 
but are not limited to, such products as  Empirin®  (paracetamol + 
codeine), Vicodin® (paracetamol +  hydrocodone),  Percocet® 
(paracetamol + oxycodone), and Zaldiar® or Ultracet® 
 (paracetamol + tramadol). Table 2 lists selected studies of 
fixed-dose combinations with paracetamol, all of them having 
demonstrated good efficacy in several chronic pain conditions.
As an example of fixed-dose combination, the participants of 
the meeting discussed tramadol/paracetamol because this prod-
uct has been more extensively evaluated than other combination 
products. The theoretical rationale for the combination agents 
described needs to be backed by clinical evidence because, in 
some cases, additive benefits do not result in clinically meaning-
ful differences. Tramadol/Paracetamol is – to our knowledge – 
the only fixed-dose combination where both the dual mechanism 
of action of tramadol and the analgesic synergy between the two 
compounds have been demonstrated in both preclinical studies 
(mouse model) and human companion studies using essentially 
the same study design.30–33 Table 3 provides an overview of 
the relevant results. Further study of tramadol/paracetamol 
combination analgesia in chronic pain syndromes is warranted 
to better evaluate long-term safety and efficacy.
According to these and later studies, the mechanisms of 
action of tramadol may be described, respectively as: a weak 
agonist effect at the µ-opioid receptors, inhibition of serotonin 
reuptake, and inhibition of norepinephrine reuptake.98 
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Figure 1 Representation of isobolographic analysis. Equi-effective doses of two 
drugs are determined (A) and graphed on Cartesian coordinates (B). The predicted 
effect of various ratios of combinations of these drugs is simple additivity (C). Actual 
results on, above, or below the predicted line of additivity (D) are indicative of 
additive, sub-additive, or supra-additive (synergistic) interaction, respectively.
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Table 2 Selected clinical studies using fixed-dose combination products with paracetamol
Study N Agents Results Comments
Postoperative pain
Dental
Fricke et al139 
Double-blind,  
randomized
200 •  Tramadol/APAP 37.5 mg/325 mg
•  Tramadol/APAP 75 mg/650 mg
•  Hydrocodone/APAP 10 mg/650 mg
•  Placebo
•  Single dose
•  Comparable analgesia between tramadol/
ATAP 75 mg/650 mg and hydrocodone/
APAP but better tolerability for  
tramadol/ATAP
•  Nausea and vomiting were 50% lower  
with tramadol/APAP 75 mg/650 mg than 
with hydrocodone/APAP
Removal of $2 impacted 
third molars
MacLeod et al140 
Double-blind,  
randomized,  
parallel-group
82 •  Codeine/APAP 30 mg/1000 mg
•  APAP 1000 mg
•  3 doses over 8 hours
•  Combination significantly more effective  
in pain control
•  Similar AE incidences
Removal of impacted third 
molars
Edwards et al141 
Meta-analysis,  
randomized studies
5  
studies
•  Tramadol/APAP 75 mg/650 mg  
or 112.5 mg/975 mg
•  Tramadol 75 mg
•  Single dose
•  NNT for at least 50% pain relief over  
6-hour period:
 – 2.6 tramadol/APAP 
 – 9.9 tramadol
NNH was 5.4 (4.0–8.2)  
for tramadol/APAP and  
5.0 (3.7–7.3) for tramadol
Jung et al142 
Randomized
128 •  Tramadol/APAP 75 mg/650 mg
•  Codeine/APAP/ibuprofen  
20 mg/500 mg/400 mg
•  Single dose
•  Comparable onset of analgesia, analgesic 
efficacy, and safety profile
Extraction of $1 
impacted third molar 
requiring bone removal
Litkowski et al143 
Double-blind,  
randomized,  
placebo-controlled,  
parallel-group
249 •  Oxycodone/ibuprofen 5 mg/400 mg
•  Oxycodone/APAP 5 mg/325 mg
•  Hydrocodone/APAP 7.5 mg/500 mg
•  Placebo
•  Single dose
•  Oxycodone/Ibuprofen with significantly 
better pain relief than other treatments
•  AE rate of oxycodone/ibuprofen similar  
to placebo and 2-fold lower to other  
2 active agents
Removal of 2 or more 
impacted third molars
Daniels et al144 
Double-blind,  
randomized,  
parallel-group,  
placebo-controlled
678 •  Ibuprofen/APAP 400 mg/1000 mg
•  Ibuprofen/APAP 200 mg/500 mg
•  Ibuprofen/codeine 400 mg/25.6 mg
•  Codeine/APAP 30 mg/1000 mg
•  Placebo
•  Single dose
•  Both doses of ibuprofen/APAP with 
significantly more effective pain relief  
than placebo and codeine/APAP
•  Ibuprofen/APAP 400 mg/1000 mg 
significantly superior to ibuprofen/ 
codeine; ibuprofen/APAP 200 mg/500 mg  
noninferior to ibuprofen/codeine
•  AE rates were higher for codeine 
combinations
Removal of $3 impacted 
third molars
Other procedures
White et al145 
Double-blind,  
randomized,  
parallel-group
252 •  Hydrocodone/APAP  
7.5 mg/750 mg
•  Ketorolac 10 mg
•  Placebo
•  Every 6 hours for up to 3 days
•  No difference in pain relief between the 
active agents after arthroscopic  
procedures, both superior to placebo
•  No difference in pain relief between all  
3 groups for laparoscopic procedures
•  AE incidences similar for both active  
agents, except higher incidence of 
postoperative dizziness for  
hydrocodone/APAP
Ambulatory arthroscopic 
or laparoscopic tubal 
ligation
Palangio et al146 
Double-blind,  
randomized,  
placebo-controlled
180 •  Hydrocodone/ibuprofen  
15 mg/400 mg
•  Oxycodone/APAP 10 mg/650 mg
•  Placebo
•  Single dose
•  Both active combinations provided 
significantly better pain relief than  
placebo; hydrocodone/ibuprofen superior  
to oxycodone/APAP at some time points
•  AEs similar for active agents
Obstetric or gynecological 
surgery
Smith et al132 
Double-blind,  
randomized,  
placebo-controlled
305 •  Tramadol/APAP 75 mg/650 mg
•  Codeine/APAP 60 mg/600 mg
•  Placebo
•  Mean daily dose:
 – tramadol/APAP 163 mg/1415 mg 
 – codeine/APAP 130 mg/1296 mg
•  Both active combinations provided 
significantly greater pain relief than  
placebo; scores were similar for  
tramadol/APAP and codeine/APAP
•  Tramadol/APAP was better tolerated  
than codeine/APAP but AE rates were  
similar for both active groups
Orthopedic and 
abdominal surgery
(Continued)
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Table 2 (Continued)
Study N Agents Results Comments
Sniezek et al147 
Double-blind,  
randomized
210 •  APAP 1000 mg
•  Ibuprofen/APAP 400 mg/1000 mg
•  Codeine/APAP 30 mg/ 325 mg
•  Immediately after surgery and  
every 4 hours for up to 4 doses
•  Ibuprofen/APAP superior to other  
2 treatments in pain control
•  Higher rate of AEs under codeine/APAP 
compared with ibuprofen/APAP and  
APAP alone
Mohs micrographic 
surgery and 
reconstruction for head 
and neck skin cancer
Rawal et al148  
Randomized,  
double-blind,  
double-dummy,  
parallel-group
261 •  Tramadol/APAP 37.5 mg/325 mg
•  Tramadol 50 mg
•  Before and immediately after  
surgery and every 6 hours  
thereafter
•  Comparable analgesic efficacy, fewer AEs 
with tramadol/APAP compared  
with tramadol monotherapy
•  Tramadol/APAP reduced tramadol 
consumption by 24%
Ambulatory hand surgery 
with iv regional anesthesia
Musculoskeletal pain
Mullican and  
Lacy131 
Double-blind,  
randomized
462 •  Tramadol/APAP 37.5 mg/325 mg
•  Codeine/APAP 30 mg/300 mg
•  Mean daily dose:
 – Tramadol/APAP 131 mg/1133 mg 
 – Codeine/APAP 105 mg/1054 mg
•  Comparable efficacy, better tolerability  
for tramadol/APAP
Chronic, nonmalignant 
low back pain and 
osteoarthritis pain
Serrie et al149 
Observational,  
prospective,  
open-label, in clinical  
practice (ELZA),  
mean therapy  
duration 16.6 days
5495 •  Tramadol/APAP 37.5 mg/325 mg
•  Mean daily dose 139 mg/1203 mg
•  Significant reduction from baseline in  
mean pain intensity score
•  4.2% of patients with AEs
Majority of patients had 
musculoskeletal pain
Mejjad et al150 
Observational,  
prospective,  
open-label, in clinical  
practice (SALZA),  
median treatment  
30 days
2663 •  Tramadol/APAP 37.5 mg/325 mg
•  Mean daily dose 143 mg/1235 mg
•  Marked reduction from baseline in mean 
pain intensity score (from 6.1 ± 1.6 at  
baseline to 3.0 ± 1.8 at final assessment)
•  91% of patients were satisfied or  
completely satisfied
•  Rate of AEs was 4.5%
Patients aged $  
65 years, primarily with 
musculoskeletal pain
Osteoarthritis
Emkey et al151 
Double-blind,  
randomized,  
placebo-controlled
306 •  Tramadol/APAP 37.5 mg/325 mg
•  Placebo
•  Mean daily dose 154 mg/1332 mg
•  Significant pain relief, significant 
improvement in medical assessments, 
physical function, and subject’s and 
investigator’s overall assessment
•  13% of tramadol/APAP and 4% of placebo 
patients discontinued owing to AEs
Add-on for patients with 
inadequate pain control 
by celecoxib or rofecoxib
Corsinovi et al152 
Randomized,  
single-blind
154 •  Average dose at end of study:
 – Oxycodone/APAP 16 mg/900 mg 
 – Codeine/APAP 115 mg/1916 mg 
•  Conventional therapy (NSAIDs,  
APAP, COX-2 inhibitors)
•  Significantly greater pain reductions for 
oxycodone/APAP and codeine/APAP 
compared with conventional therapy
•  AE rates did not differ between groups
Elderly females
Pareek et al153 
Randomized,  
open-label
199 •  Aceclofenac/APAP  
100 mg/500 mg bid
•  Aceclofenac 100 mg bid
•  Combination superior in pain intensity 
differences, sum of pain intensity  
differences, peak pain intensity  
differences and patients’/ 
investigators’ assessments
•  Combination had more rapid onset  
of action
•  AE rate similar in both groups
Knee flare-up
Pareek et al154
Randomized,  
double-blind
220 •  Etodolac/APAP  
300 mg/ 500 mg bid
•  Etodolac 300 mg bid
•  Compared with etodolac monotherapy, 
etodolac/APAP was superior in reducing  
pain intensity and improvement of  
function
•  Results noticeable within 30 minutes  
of first dose
•  Similar AE rates for both groups
Knee flare-up
(Continued)
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Table 2 (Continued)
Study N Agents Results Comments
Doherty et al155 
Double-blind,  
randomized,  
parallel-group
892 •  Ibuprofen 400 mg tid
•  APAP 1000 mg tid
•  Ibuprofen/APAP 200 mg/500 mg tid
•  Ibuprofen/APAP 400 mg/1000 mg tid
•  Ibuprofen/APAP, at nonprescription  
doses, confers modest short-term  
benefits
•  Decreases in hemoglobin by $1 g/dL 
occurred in all groups but were twice as 
frequent in patients taking 2 combination 
tablets daily compared with monotherapy
$40 years of age 
Chronic knee pain,  
85% osteoarthritis
Conaghan et al156 
Open-label,  
randomized,  
parallel-group
220 •  7-day buprenorphine patches  
(range 5–25 µg/hour) +  
APAP 1000 mg qid
•  Codeine/APAP range 16–60 mg/ 
1000 mg qid
•  Noninferiority of patch + APAP to  
codeine/APAP combination regarding  
analgesic efficacy
•  Comparable incidence of AEs
•  High withdrawal rates in both groups
•  Hip and/or knee pain
•  $60 years of age
Low back pain
Palangio et al157 
Double-blind,  
randomized,  
parallel-group
147 •  Hydrocodone/ibuprofen  
7.5 mg/200 mg
•  Oxycodone/APAP 5 mg/325 mg
•  Mean daily dose:
 –  Hydrocodone/ibuprofen  
13.5 mg/360 mg
 – Oxycodone/APAP 11 mg/715 mg
•  No significant differences between the 
groups in efficacy and AEs
Acute pain
Ruoff et al158 
Double-blind,  
randomized
318 •  Tramadol/APAP 37.5 mg/325 mg
•  Placebo
•  Mean daily dose 158 mg/1365 mg
•  Significantly improved outcome in all  
efficacy measures compared with placebo
•  Discontinuation due to AEs was 19% for 
combination and 6% for placebo
Chronic pain
Perrot et al159 
Double-blind,  
randomized,  
parallel-group
119 • Tramadol/APAP 37.5 mg/325 mg 
• Tramadol 50 mg 
• Mean daily dose: 
 – Tramadol/APAP 172 mg/1495 mg 
 – Tramadol 227 mg
•  Comparable analgesic efficacy with 
significantly fewer AEs with tramadol/ 
APAP
•  Tramadol/APAP reduced tramadol 
consumption by 24%
Subacute pain
Fibromyalgia
Bennett et al160 
Double-blind,  
randomized,  
placebo-controlled
315 •  Tramadol/APAP 37.5 mg/325 mg
•  Placebo
• Mean daily dose 150 mg/1300 mg
•  Significantly better pain relief and health-
related QoL with combination therapy
•  Discontinuation due to AEs was 19% for 
combination and 12% for placebo
Rheumatoid arthritis
Lee et al161 
Double-blind,  
randomized,  
placebo-controlled
277 •  Tramadol/APAP  
37.5 mg/325 mg tid
•  Placebo
•  Significant improvement in pain relief, 
significant reduction in pain intensity,  
no difference in physical function, 
significantly higher rate of AEs
•  Discontinuation due to AEs was 19% for 
combination and 3% for placebo
Add-on for patients with 
inadequate pain control 
by conventional NSAIDs 
and DMARDs
Raffaeli et al162
Open-label,  
case series
29 •  Oxycodone/APAP 5 mg/325 mg
•  Mean daily dose at end of study
•  14 mg/720 mg
•  42% had good clinical response (EULAR)  
and 50% showed 20% improvement
•  No serious AEs
Patients under 
rheumatoid arthritis 
therapy with biological 
drugs were excluded
Painful diabetic neuropathy
Freeman et al130 
Double-blind,  
randomized,  
placebo-controlled,  
parallel-group
313 •  Tramadol/APAP 37.5 mg/325 mg
•  Placebo
•  Mean daily dose 158 mg/1365 mg
•  Significantly greater improvements for all 
measures of pain intensity, sleep  
interference, and global impression as  
well as several QoL measures and mood
•  AE rate was 60% for the combination  
and 59% for placebo, nausea, dizziness,  
and somnolence significantly more  
common under combination
•  Discontinuation due to AEs was 8% for 
combination and 6.5% for placebo
(Continued)
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Table 2 (Continued)
Study N Agents Results Comments
Ko et al129 
Open-label,  
randomized
163 •  Tramadol/APAP 37.5 mg/325 mg 
• Gabapentin 300 mg
•  Mean dose at final visit:
 – Tramadol/APAP 158 mg/1371 mg 
 – Gabapentin 1575 mg
•  Comparable mean reductions in pain 
intensity and mean pain relief scores
•  Comparable improvements in QoL
•  Similar rates of AEs and discontinuation  
due to AEs for both groups
Patients with type 2 
diabetes aged 25–75 years 
Dose adjusted to effect, 
no rescue medication 
during maintenance phase
Abbreviations: AEs, adverse events; APAP, paracetamol (acetaminophen); bid, twice daily; DMARD, disease-modifying antirheumatic drug; iv, intravenous; NSAIDs, 
nonsteroidal anti-inflammatory drugs; NNH, number needed to harm; NNT, number needed to treat; qid, four times per day; QoL, quality of life; tid, three times per day.
Table 3 Companion studies demonstrating mode of action of tramadol/paracetamol fixed-dose combination
Dual mechanism of action of tramadol Analgesic synergy between tramadol and paracetamol
Mouse and rat model30 Healthy male volunteers32 Mouse model31 Healthy volunteers33
Design Double-blind, randomized, 
placebo-controlled, crossover
Double-blind, randomized,  
placebo-controlled, crossover
Agents Tramadol iv •  Tramadol 100 mg oral dose
•  3 hours later, either placebo 
injection or yohimbine iv  
0.1 mg kg−1 +placebo or 
yohimbine + naloxone  
(µ opioid antagonist)  
0.8 mg iv
Oral: 
•  APAP
•  Tramadol
•  Tramadol/APAP using  
different fixed dose ratios  
(TRAM/APAP ratios  
tested were: 1000:1,  
100:1, 20:1, 3:1, 1:1,  
1:3, 1:5, 1:5.7, 1:19,  
1:50, 1:100: 1:200,  
1:800, and 1:1600)
iv infusions: 
•  APAP 650 mg
•  Tramadol 75 mg
•  Tramadol/APAP 37.5 mg/325 mg
•  Placebo
Methods •  Mouse acetylcholine-induced 
abdominal constriction test
•  Rat air-induced abdominal 
constriction test
•  Mouse/rat hotplate and  
tail-flick tests
•  Yohimbine (α2-adrenoceptor 
antagonist) and ritanserin  
(5HT2A/2C antagonist)  
antagonism in rats and mice
•  Induction of pain by  
electrical stimulus
•  Assessment of subjective  
pain threshold (pain intensity 
rating) and objective pain 
threshold (R III nociceptive 
reflex) for 8 hours after 
tramadol intake
•  Acetylcholine bromide 
injection 30 minutes  
after analgesia delivery
•  Assessment: occurrence 
of a single abdominal 
constriction response
•  Estimation of ED50 from 
individual dose– 
response curves
•  Induction of acute pain and 
mechanical hyperalgesia by tran-
scutaneous electrical stimula-
tion at high current densities
•  Drugs were delivered in a  
15-minute infusion starting  
30 minutes after onset of 
electrical stimulation
•  Assessments before, during,  
and 150 minutes after infusion
Results •  Tramadol produced  
dose-related anti-nociception  
in all tests
•  This anti-nociceptive activity  
was completely antagonized  
by naloxone
•  Administration of yohimbine  
or ritanserin blocked anti- 
nociceptive activity produced  
by tramadol but not the one  
produced by morphine
•  Tramadol induced a  
significant increase in  
both thresholds
•  Yohimbine almost totally 
reversed the subjective (67%) 
and objective (97%)  
anti-nociceptive effect of 
tramadol for 2.8 hours
•  Addition of naloxone  
abolished tramadol effects  
(79% for subjective, 90% for  
objective pain threshold)
ED50 values: 
•  Tramadol 5.5 ± 0.4
•  APAP 164.9 ± 24.5
Pain reduction  
(correction for placebo effects) 
•  Tramadol 11.7% ± 4.2%
•  APAP 9.8% ± 4.4%
•  Tramadol/APAP 15.2% ± 5.7%
Anti-hyperalgesic effect  
(correction for placebo effects) 
•  Tramadol 7.4% ± 8.1%
•  APAP 34.5% ± 14%
•  Tramadol/APAP 41.1% ± 14.3%
Conclusions The results suggest that  
tramadol-induced anti- 
nociception is mediated by  
opioid (µ) and nonopioid  
(inhibition of monoamine  
uptake) mechanisms
Alpha2-adrenoceptor  
antagonism reverses tramadol  
effects, thus pointing to  
significant role of  
monoaminergic modulation  
and synergy with opioid 
antagonism in tramadol  
anti-nociception
Supra-additive effects of the 
combination regarding analgesia  
and anti-hyperalgesia
Abbreviations: APAP, paracetamol (acetaminophen); ED50, the dose of a drug that is pharmacologically effective for 50% of the population exposed to the drug or a 50% 
response in a biological system that is exposed to the drug; iv, intravenous.
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In a preclinical model, it has been shown that the nonopioid 
component in tramadol may enhance its potency ratio relative 
to morphine in neuropathic pain models.99 Tramadol can 
increase the risk of convulsions in patients who are taking 
medicinal products reducing the seizure threshold such as 
bupropion, serotonin reuptake inhibitor antidepressants, 
tricyclic antidepressants and neuroleptics. In isolated 
cases there have been reports of serotonin syndrome in a 
temporal connection with the therapeutic use of tramadol 
in combination with other serotoninergic medicines such 
as selective serotonin reuptake inhibitors.100 The second 
component in this fixed-dose combination, paracetamol, 
appears to act at both central and peripheral pathways,101 
but its exact mechanism(s) of action has/have yet to be 
thoroughly elucidated. The maximum recommended adult 
dose of paracetamol is 4 g/day.102,103 At therapeutic doses, 
paracetamol is rarely associated with hepatotoxicity.104
Complementary pharmacokinetics of tramadol/ 
paracetamol in combination enhance the probability of 
effective pain relief (Figure 2) and supra-additive effects of 
the combination regarding analgesia and anti-hyperalgesia 
have been demonstrated in a human pain model.33 Clinical 
studies have shown good efficacy and safety of this fixed-dose 
product for a variety of pain conditions.105,106 Details from 
selected studies can be found in Table 2.
Mitigation strategies when 
prescribing high-dose NSAIDs  
or high-dose paracetamol
Before high-dose paracetamol or high-dose NSAIDs are con-
sidered for patients, mitigation strategies should be undertaken, 
including the review of patients to verify if they are appropri-
ate candidates for such therapy in light of their comorbidities 
and co-medications.107 Upper gastrointestinal adverse 
effects can be mitigated by proton pump inhibitors.108–112 
Patients on long-term high-dose paracetamol or NSAID 
therapy should be educated as to the potential risks of these 
drugs, the doses, and the fact that these agents may be contained 
in a variety of prescription and over-the-counter products. In 
the USA, this has been called a “do ask, do tell” strategy, where 
clinicians are encouraged to ask patients about their use of con-
comitant medications, including over-the-counter products and, 
by the same token, patients are encouraged to fully disclose to 
their clinicians all of the drugs they take.113 For many patients, it 
may be appropriate to use a low-dose combination product for 
maintenance, with occasional NSAIDs to treat breakthrough 
episodes. An individualized approach to mid- and long-term 
pain management is required in light of the potential risks and 
benefits of analgesic agents (Table 4).114
The mitigation of adverse events is more than just a matter 
between clinician and patient. We recommend the use of plain 
language in labeling over-the-counter products and prescribed 
medications that contain paracetamol and/or NSAIDs to help 
patients in monitoring their own daily and cumulative doses. 
Comprehensive educational efforts are required to alert patients 
to the dangers of many over-the-counter analgesics and to 
inform them of appropriate doses and how to calculate them. 
Many patients consider over-the-counter products “harmless” 
and may take these agents casually. Patient education should 
include “do ask, do tell,” such that patients understand the impor-
tance of discussing with their clinicians all drugs they take.
Current guidelines and pain 
management in specific populations
When it comes to pain management, there is no lack of 
literature, including consensus statements and guidelines. 
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submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
336
Pergolizzi Jr et al
Journal of Pain Research 2012:5
Yet, pain is undertreated. Up to 27% of people with con-
stant or daily musculoskeletal pain never seek treatment 
and many people with chronic pain seek medical help for 
the first time only after a year or more of pain.115 It may be 
inferred that many people feel pain as something they have 
to live with or that clinicians are unable to treat pain effec-
tively. Between 28% and 54% of patients with musculosk-
eletal pain under medical care do not take any prescription 
analgesics.115 Further, patients may have serious concerns 
about analgesics; for example, 65%–77% of pain patients 
considering opioid analgesics have fears of tolerance or 
addiction.115
Many guidelines for the management of pain in specific 
populations exist.27,29,79,81,116–127 These guidelines are largely 
evidence-based documents, but at times the absence of 
evidence is construed as the evidence of absence. Important 
topics in pain management, such as, but not limited to, the 
transition from acute to chronic pain, are not addressed 
by the guidelines. In general, the guidelines tend to stress 
avoidance of adverse events at the expense of efficacy in the 
treatment of moderate to severe pain. The American Heart 
Association scientific statement recommends a stepped-
care approach to pharmacological therapy for musculo-
skeletal pain patients with known cardiovascular disease or 
at risk for ischemic heart disease that emphasizes avoidance 
of potential risk at the expense of pain relief.29
Elderly patients
Chronic pain is both common and especially challeng-
ing to treat in geriatric patients, who often suffer from 
comorbidities. Chronic pain adversely affects the quality 
of life, mobility, and mood, and may limit daily activities 
and social pursuits in patients of all ages, but younger 
patients may be more resilient or better able to cope with 
these limitations than older patients. According to the most 
recent guidelines issued by The American Geriatrics Soci-
ety, NSAIDs for the treatment of chronic pain should be 
avoided in patients aged 75 years or older; NSAIDs should 
be “considered rarely, and with extreme caution, in highly 
selected individuals.”27 Paracetamol should be considered as 
the initial and ongoing therapy of choice except for patients 
with a known liver disease. The maximum recommended 
daily dose of paracetamol is 4 g/24 hours and should not 
be exceeded. This maximum daily intake must include hid-
den sources in other medications. All patients with moder-
ate to severe pain, pain-related functional impairment, or 
diminished quality of life due to pain should be consid-
ered for opioid therapy.27
Overview on experience with 
fixed-dose tramadol/paracetamol 
in the treatment of moderate to 
severe pain in nonacute conditions: 
differences to NSAIDs
NSAIDs are frequently prescribed analgesic agents but recent 
warnings – including a US Food and Drug Administration 
labeling proposal that all NSAIDs should be prescribed 
at the lowest possible doses for the shortest possible 
duration128 – have caused many clinicians to reevaluate these 
effective painkillers. Recently, new combination analgesic 
products based on scientifically reasonable design have been 
introduced to the market to offer effective analgesia with a 
good risk/benefit ratio. The combination product tramadol/
paracetamol may be an important aid for the treatment of 
acute and chronic pain syndromes (Table 5).
Pain involving multiple mechanisms, can be safely and 
effectively treated with combination analgesics, for example, 
Table 4 Mitigation strategies that may be useful for patients receiving paracetamol or nonsteroidal anti-inflammatory drugs (NSAIDs) 
for pain management
Area of concern Mitigating strategies
Labeling of paracetamol, acetaminophen, and combination  
products, particularly over-the-counter preparations
Plain language labeling 
Patient education initiatives about high-dose, long-term, and cumulative doses of 
paracetamol and NSAIDs 
“Do ask, do tell” approach
High-dose paracetamol seems necessary Consider lower doses of paracetamol in combination with other pain medication 
due to risk of hepatotoxicity, hypertension, and gastrointestinal complications
High-dose NSAID seems necessary Consider lower doses used in combination with other pain relievers on account 
of increased risk for gastrointestinal complications and particularly in light of risk 
factors (old age, ulcer history, smoking, comorbidities) 
Add proton pump inhibitor 
Limit dose
NSAID seems necessary in a patient with a cardiovascular risk Consider the lowest possible dose of NSAIDs or avoid NSAIDs altogether.  
An alternative might be a low-dose fixed combination product
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tramadol/paracetamol.129,130 However, there are few direct 
comparative studies of combination products – for instance, 
codeine/paracetamol versus tramadol/paracetamol.131–133
Long-term pain management recommendations often 
feature NSAIDs as a first-line treatment for rheumatic 
diseases,134,135 with added opioid combination analgesics for 
flares.136–138 A possible new paradigm would be to treat pain 
first with opioid combination analgesics then use NSAIDs to 
manage flares. Table 6 summarizes the strengths and weak-
nesses of NSAIDs versus tramadol/paracetamol fixed-dose 
combination products.
Recent guidelines for pain management and the position 
of paracetamol, NSAIDs, and fixed-dose combinations such 
as tramadol/paracetamol are shown in Table 7.
Consensus statements
The group arrived at several consensus statements. These 
follow, grouped by topic.
Pain management
• There are many reasons why pain management is com-
plex, including the classification of pain, mechanisms, 
knowledge, individualization, lack of universally accepted 
guidelines, social and psychological factors, as well as 
various influences from the health care system itself. 
Nevertheless, not treating pain is not an option.
• Individualization of treatment in patients suffering from 
moderate to severe pain should be the ultimate goal of 
the health care team.
• Pain management guidelines must take into consider-
ation the type of pain, its intensity, the particular patient 
characteristics, and expected duration of treatment. This 
requires a multidimensional approach, which creates 
difficulty in making generalized recommendations.
• Many evidence-based guidelines for pain management 
are available, but none is universally accepted by all 
health care providers. These guidelines may benefit 
Table 6 Strengths and weakness of tramadol/paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs)
NSAIDs Tramadol/paracetamol
Strengths •  Frequently prescribed
•  Ubiquitous
•  Gold standard for many conditions: ibuprofen
•  Well tolerated short term
•  Over-the-counter availability
•  Recent combination of established analgesics with scientifically 
and clinically based rationale
•  Good benefit–risk balance
•  No specific warnings
Weaknesses •  Recent warnings
•  Safety profile (gastrointestinal, renal, and cardiovascular risks)
•  Coadministration with other drugs
•  Combination therapy not well established
•  Difficult to differentiate from tramadol immediate release, 
tramadol extended release
•  Not well tolerated short term
Table 5 Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) with tramadol/paracetamol fixed-dose combination
Selective and nonselective NSAIDs Tramadol/paracetamol combination
Pain severity For mild to moderate pain For moderate to severe pain
Clinical application Wide, including rheumatic disorders,  
headaches, visceral pain
Wide, indicated for symptomatic relief of moderate  
to severe pain
Acute vs chronic pain Both Both
Neuropathic pain No, exclusively for pain related to tissue  
damage and/or inflammation
Yes129,130
Anti-inflammatory effect Yes No
Pediatric use Yes No
Geriatric use With caution27 May be appropriate27,150
Use in patients with renal failure No163 Not recommended for severe renal insufficiency  
(creatinine clearance , 10 mL/min) but may be used at 
reduced dose in patients with moderate renal insufficiency 
(creatinine clearance between 10 and 30 mL/min)  
Tramadol is removed only very slowly by hemodialysis or 
hemofiltration, so post-dialysis administration to maintain 
analgesia is usually not required
Co-medications Caution with diuretics, anticoagulants,  
angiotensin-converting-enzyme inhibitors
Caution with other central nervous system depressants, 
selective serotonin reuptake inhibitors164
Use with concomitant opioids May be synergistic86 Overdose considerations
Use with anticonvulsants Not known Not known
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Table 7 Summary of guidelines and recommendations for paracetamol (APAP), nonsteroidal anti-inflammatory drugs (NSAIDs), and 
combination products such as tramadol (tram)/paracetamol
Guideline APAP NSAIDs Combination  
(tram/APAP)
Comments
Osteoarthritis (OA)
Management of OA  
Altman overview117
1st (Yes) Yes NSAIDS for anti-inflammatory action
Early management of OA  
Altman overview118
1st (2nd) 3rd Oral NSAIDs at their lowest effective dose; 
long-term use should be avoided
NICE OA guideline81 1st 2nd with PPI – Oral NSAIDs/COX-2 inhibitors should be used 
at the lowest effective dose for the shortest 
possible period of time
OARSI guidelines79 1st (2nd) – Oral NSAIDs at lowest effective dose;  
long-term use should be avoided 
ACR Guidelines165
Hand OA
Knee OA
Hip OA
No
1st
1st 
1st
2nd 
2nd 
–
–
–
Topical or oral NSAIDs; topical NSAIDs for 
persons ≥75 years of age recommended
Health care providers should be aware of the 
warnings and precautions associated with topical 
and oral NSAIDs
Oral NSAIDs; no recommendation on topical 
NSAIDs
Rheumatoid arthritis (RA)
NICE RA guideline119 1st (2nd + PPI) 1st (compound 
analgesics in general)
Oral NSAIDs/COX-2 inhibitors should be used 
at the lowest effective dose for the shortest 
possible period of time
BSR guidelines for early RA120 2nd  
(as add-on)
(1st) 2nd (as add-on) Long-term use of NSAIDs at lowest effective 
dose. At present, the use of single or compound 
analgesics or anti-inflammatory drugs  
(including coxibs) has to be settled  
with each individual patient  
No clear recommendations
BSR guidelines for long-term  
treatment of RA121
– 2nd as add-on  
with PPI
– No clear recommendations
EULAR recommendations  
early arthritis122
– (Yes) – NSAIDs after careful evaluation of 
gastrointestinal, renal, and cardiovascular status
Fibromyalgia
EULAR recommendations  
for fibromyalgia123
Yes – – Tramadol is one of the analgesics of choice
APS guidelines for  
fibromyalgia124
No No 3rd Tricyclic antidepressants first, serotonin 
reuptake inhibitors (SSRIs) alone or in 
combination with tricyclics second.  
Paracetamol not recommended as monotherapy, 
only in combination
Low back pain
European guidelines for chronic  
nonspecific low back pain125
– (Yes) (Yes) NSAIDs should only be used for exacerbations 
or short-term periods (up to 3 months)
APS/ACP guidelines126 1st (1st) – Oral NSAIDs at their lowest effective dose,  
for the shortest possible time required
NICE. Low back pain guideline127 1st 2nd (+ PPI  
for patients  
aged . 45 years)
– Weak opioids and strong opioids are suggested 
for more severe pain, but no combinations
Musculoskeletal pain
Schnitzer, guidelines for  
chronic musculoskeletal pain116 
Osteoarthritis
 
 
1st
 
 
No or 2nd
 
 
2nd
NSAIDs not for long-term use or 
in patients with risk factors; second  
for short-term use
(Continued)
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Table 7 (Continued)
Guideline APAP NSAIDs Combination  
(tram/APAP)
Comments
Low back pain 2nd 1st Young, healthy individuals could receive NSAIDs 
alone or at a reduced dose combined  
with paracetamol/tramadol
following injury 2nd  
as add-on
(1st) 3rd
Rehabilitation 1st 1st for pain in  
motion and  
for inflammation
2nd as add-on
Specific patient populations
AGS geriatric guidelines27 1st (2nd) + PPI or  
misoprostol
(2nd) For paracetamol, maximum daily recommended 
dosages of 4 g per 24 hours should not be 
exceeded and must include “hidden sources” 
Nonselective NSAIDs and COX-2 selective 
inhibitors may be considered rarely, and with 
extreme caution, in highly selected individuals 
All patients with moderate to severe pain, pain-
related functional impairment, or diminished 
quality of life due to pain should be considered 
for opioid therapy 
Maximal safe doses of paracetamol or NSAIDs 
should not be exceeded when using fixed-dose 
opioid combination agents
AHA guidelines29 1st (3rd) – NSAIDs at their lowest effective dose + ASA  
81 mg and PPI for patients at increased risk  
of thrombotic events
Neuropathic pain
Dworkin et al166 – – – Tramadol is recommended as second-line 
treatment 
Standard treatments such as NSAIDs and 
paracetamol have no proven efficacy against 
neuropathic pain although they are frequently 
prescribed for patients with neuropathic pain167
Notes: –, not mentioned in guideline; 1st, first-line therapy; 2nd, second-line therapy; 3rd, third-line therapy; NO, not recommended; Yes, recommended but not first-, 
second-, or third-line recommendation; (Yes), recommended with caution.
Abbreviations: ACR, American College of Rheumatology; ACP, American College of Physicians; AGS, The American Geriatrics Society; AHA, American Heart Association; 
APS, American Pain Society; ASA, acetylsalicylic acid; BSR, British Society for Rheumatology; COX, cyclooxygenase; coxibs, selective COX-2 inhibitors; EULAR, European 
League Against Rheumatism; NICE, National Institute for Health and Excellence; PPI, proton pump inhibitor.
by addressing topics such as the chronicity of pain, 
 barriers to treatment, patient preferences influencing 
pain therapy, and practical clinical considerations. 
Current guidelines mostly contain strong evidence 
for pharmacological approaches; however, they would 
benefit from the addition of considerations related 
to the evidence or absence of evidence of risks of 
drugs and inclusion of nonpharmacological treatment 
options.
The use of NSAIDs and paracetamol  
in chronic pain management
• NSAIDs and paracetamol are commonly used and com-
monly recommended agents for the management of pain 
and are helpful for many patients. However, they are not 
without potential risks, especially in the elderly and in 
patients with renal, gastrointestinal, or cardiovascular 
disease. High doses and long-term use of NSAIDs to man-
age moderate to severe pain have been associated with 
tolerability issues, including serious adverse events.
• Fixed-dose combinations provide a multi-mechanistic 
analgesic approach. Clinical studies have demonstrated 
effective management of various types of moderate to 
severe pain with mostly good tolerability.
• A new approach to managing arthritis-related pain is 
to consider the long-term use of low-dose combination 
products for moderate to severe pain, and reserving 
NSAID use for acute flares related to inflammation.
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The role of fixed-dose combinations  
in chronic pain management using  
tramadol/paracetamol as an example
• Tramadol/Paracetamol may offer distinct advantages in 
certain patient populations and for certain types of pain, 
compared with high doses of NSAIDs or paracetamol or 
when NSAIDs or paracetamol are expected to be used for 
long durations. However, long-term studies of fixed-dose 
combinations are required.
• Potential advantages of a fixed-dose tramadol/paracetamol 
analgesic product include a broader analgesic spectrum, 
a complementary pharmacokinetic profile, potentially 
synergistic analgesic effect, greater convenience 
(possibly resulting in better compliance, thus, improved 
therapy), and an improved ratio of efficacy to adverse 
effects.
Conclusion
Pain management is a global challenge to clinicians and, 
despite the plethora of evidence-based guidelines, all 
analgesic options must be individually assessed and weighed 
for specific risks and benefits in a given patient. Many 
effective analgesics exist but are associated with adverse 
events. NSAIDs and paracetamol are effective pain relievers, 
but recent studies have raised safety concerns, particularly 
when these agents are used at high doses, long-term, or in 
special patient populations. Opioid analgesics are effective 
but are associated with adverse events as well as concerns 
over tolerance and addiction. Finding an analgesic product 
that offers both effective pain relief and a good safety profile 
has led to increasing interest in combination products.
Combination agents may offer analgesic synergy that 
allows them to provide effective analgesia at reduced doses. 
However, careful study of combination agents is warranted, as 
such combination products might also exacerbate side effects. 
New fixed-dose combination products may offer an improved 
method of treating the newly recognized multi-mechanistic 
nature of pain. Studies of fixed-dose combinations such 
as tramadol/paracetamol for the treatment of chronic pain 
syndromes are promising, showing safe and effective pain 
relief with good tolerability and safety profiles.
A new practice paradigm may be to use low-dose 
paracetamol or f ixed-dose combination products, and 
NSAIDs to manage acute flares. However, further studies 
are warranted to establish the long-term efficacy and safety 
of these products.
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